The peptide endothelin receptor antagonist, TAK-044, produces sustained inhibition of endothelin-1 mediated arteriolar vasoconstriction

Aims Endothelin-1 (ET-1) has been implicated in the pathophysiology of a number of cardiovascular diseases for which endothelin receptor antagonists are currently under clinical development. We have previously reported that systemic administration of the combined endothelin A/B receptor antagonist,...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Ferro, C. J., Haynes, W. G., Johnston, N. R., Lomax, C. C., Newby, D. E., Webb, D. J.
Médium: Artigo
Jazyk:Inglês
Vydáno: 1997
Témata:
Original Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2042857/
https://ncbi.nlm.nih.gov/pubmed/9354313
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1046/j.1365-2125.1997.00595.x
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky